Proactive Investors - Run By Investors For Investors

Humanigen's new data show increase in mice survival with lenzilumab

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the company a new study evaluating lenzilumab, its flagship therapy, shows it improves the effectiveness of CAR-T, a new approach to cancer therapy involving altered T cells.

Durrant says the Burlingame, California, company is looking toward clinical studies with human patients before the end of the year.

 
View full HGEN profile View Profile

Humanigen Inc Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use